Cytokine release syndrome (CRS) has been well characterized following CD19-directed chimeric antigen receptor T-cell (CART19) in B-cell acute lymphoblastic leukemia (B-ALL). Less is known about CRS following CD22-directed CART (CART22) for B-ALL. We comprehensively examine cytokine architecture following CART22 treatment compared with CART19 treatment. Despite high disease burden, patients treated with CART22 did not experience severe CRS.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anusha
Contact Anusha, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack